Menu
Back to Journals » Neuropsychiatric Disease and Treatment » Volume 14
Aripiprazole combination for reversal of paliperidone-induced increase in prolactin level
Authors Zhi P, Wang Y, Quan W, Su Y, Zhang H
Received 3 March 2018
Accepted for publication 1 June 2018
Published 27 August 2018 Volume 2018:14 Pages 2175—2179
DOI https://doi.org/10.2147/NDT.S167129
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Professor Wai Kwong Tang
Pu Zhi,1,* Yanqiong Wang,1,* Wei Quan,1,2 Yanli Su,1 Hui Zhang1
1Department of Psychiatry, Xi’an Mental Health Center, Institute of Mental Health, Xi’an Medical University, Xi’an, China; 2Department of Natural Medicine, Institute of Materia Medica, School of Pharmacy, Fourth Military Medical University, Xi’an, China
*These authors contributed equally to this work
Abstract: Hyperprolactinemia is a common side effect of antipsychotic drugs. Although changes of antipsychotic drugs or reduction of their doses can solve this problem, a modification of the treatment regimen can lead to instability in patients. Herein, we followed up a patient with elevated prolactin caused by paliperidone and found that the prolactin level was decreased after the administration of a combination with a low-dose aripiprazole. In addition, we summarized and analyzed the findings from the case and the literature review conducted.
Keywords: aripiprazole, schizophrenia, prolactin
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.